Effects of Tau Domain-Specific Antibodies and Intravenous Immunoglobulin on Tau Aggregation and Aggregate Degradation
Abstract
Tau pathology, including neurofibrillary tangles, develops in Alzheimer’s disease (AD). The aggregation and hyperphosphorylation of tau are potential therapeutic targets for AD. Administration of anti-tau antibodies reduces tau pathology in transgenic “tauopathy” mice; however, the optimal tau epitopes and conformations to target are unclear. Also unknown is whether intravenous immunoglobulin (IVIG) products, currently being evaluated in AD trials, exert effects on pathological tau. This study examined the effects of anti-tau antibodies targeting different tau epitopes and the IVIG Gammagard on tau aggregation and preformed tau aggregates. Tau aggregation was assessed by transmission electron microscopy and fluorescence spectroscopy, and the binding affinity of the anti-tau antibodies for tau was evaluated by enzyme-linked immunosorbent assays. Antibodies used were anti-tau 1–150 (“D-8”), anti-tau 259–266 (“Paired-262”), anti-tau 341–360 (“A-10”), and anti-tau 404–441 (“Tau-46”), which bind to tau’s N-terminus, microtubule binding domain (MBD) repeat sequences R1 and R4, and the C-terminus, respectively. The antibodies Paired-262 and A-10, but not D-8 and Tau-46, reduced tau fibrillization and degraded preformed tau aggregates, whereas the IVIG reduced tau aggregation but did not alter preformed aggregates. The binding affinities of the antibodies for the epitope for which they were specific did not appear to be related to their effects on tau aggregation. These results confirm that antibody binding to tau’s MBD repeat sequences may inhibit tau aggregation and indicate that such antibodies may also degrade preformed tau aggregates. In the presence of anti-tau antibodies, the resulting tau morphologies were antigen-dependent. The results also suggested the possibility of different pathways regulating antibody-mediated inhibition of tau aggregation and antibody-mediated degradation of preformed tau aggregates.
Cited By
This article is cited by 7 publications.
- Richard Y.-C. Huang, Roxana E. Iacob, Sethu Sankaranarayanan, Ling Yang, Michael Ahlijanian, Li Tao, Adrienne A. Tymiak, Guodong Chen. Probing Conformational Dynamics of Tau Protein by Hydrogen/Deuterium Exchange Mass Spectrometry. Journal of the American Society for Mass Spectrometry 2018, 29 (1) , 174-182. https://doi.org/10.1021/jasms.8b05662
- Yung-Chih Kuo, Rajendiran Rajesh. Challenges in the treatment of Alzheimer’s disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors. Expert Review of Neurotherapeutics 2019, 19 (7) , 623-652. https://doi.org/10.1080/14737175.2019.1621750
- Dante J. Marciani. Development of an Effective Alzheimer’s Vaccine. 2018,,, 149-169. https://doi.org/10.1016/B978-0-12-809819-6.00011-3
- Chuanzhou Li, Jürgen Götz. Tau-based therapies in neurodegeneration: opportunities and challenges. Nature Reviews Drug Discovery 2017, 16 (12) , 863-883. https://doi.org/10.1038/nrd.2017.155
- Andrea C. Klaver, Mary P. Coffey, David A. Bennett, David A. Loeffler. Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study. Translational Neurodegeneration 2017, 6 (1) https://doi.org/10.1186/s40035-017-0100-x
- Robert A. Stern, Yorghos Tripodis, Christine M. Baugh, Nathan G. Fritts, Brett M. Martin, Christine Chaisson, Robert C. Cantu, James A. Joyce, Sahil Shah, Tsuneya Ikezu, Jing Zhang, Cicek Gercel-Taylor, Douglas D. Taylor, . Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy. Journal of Alzheimer's Disease 2016, 51 (4) , 1099-1109. https://doi.org/10.3233/JAD-151028
- Jose O. Esteves-Villanueva, Sanela Martic-Milne. Electrochemical detection of anti-tau antibodies binding to tau protein and inhibition of GSK-3β-catalyzed phosphorylation. Analytical Biochemistry 2016, 496 , 55-62. https://doi.org/10.1016/j.ab.2015.12.002